This mechanism is unlikely to be the explanation for the treatment efficacy observed in MHG-DLBCL, which has been suggested to be attributed to MYC-driven proteolytic stress, sensitizing cells to bortezomib [16]. Here, MYC is linked to diffuse large B-cell lymphoma.